



RESEARCH & INNOVATION 2023

ACCELERATING FUTURE
DRUG DISCOVERY

29TH & 30TH MARCH 2023
HINXTON,
CAMBRIDGE

#ELRIG

#RI2023

#RESEARCHINNOVATION2023

 elrig.org

 [@ELRIG_UK](https://twitter.com/ELRIG_UK)

 [elrig](https://www.linkedin.com/company/elrig)

ABOUT ELRIG

The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organisation that exists to provide outstanding scientific content to the life science community. The foundation of the organisation is based on the use and application of automation, robotics and instrumentation in life science laboratories, however over time, we have evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionise drug discovery.

Our community is made up of over 22,000 life sciences professionals who participate in our Conferences, Forums and Networking Events. We enable our community to exchange information and ideas within, and across, scientific disciplines as well as across the sector including academia, industry, CROs, SMEs and suppliers. We strongly believe that high quality scientific content should be accessible to everybody in our community and that is why all our events are open access and free-of-charge for all our delegates!

OUR VALUES

Our values are to always ensure we deliver the highest quality content which is accessible to everyone; to remain an inclusive organisation that serves a diverse scientific network; and ELRIG will always be volunteer led - run by, and for, the life sciences community on a not-for-profit basis

OUR PURPOSE

ELRIG is a company whose purpose is to bring the life science and drug discovery communities together to learn, share, connect, innovate and collaborate, on an open access basis. We achieve this through the provision of world class conferences, networking events, webinars and digital content.

GOVERNANCE

ELRIG's board is comprised of volunteers from it's community, who either work in biopharma, CRO's, academia or with vendor companies. The board is steered by the General Committee, who act as a direct connection to the community and thus is comprised of a diverse group of people. The board delegates it's tasks to a series of work groups, who work with the Operational Team to ensure ELRIG achieves it's objectives. Current work groups are:

- Early Career Professionals
- Marketing Communications
- Networking & Webinars
- People & Culture
- Publications
- Science Strategy
- Vendor Outreach

STRATEGIC PILLARS



EVENTS

Deliver UK leading events, showcasing cutting edge science and technology, that are accessible to all.



EQUALITY, DIVERSITY & INCLUSIVITY

Promote inclusivity, engagement and collaboration, in our diverse community.



PRESENCE & AWARENESS

Expand and enhance our digital presence.



SUSTAINABILITY

Drive an open and transparent organisation, with a focus on delivery excellence and financial sustainability.

ELRIG'S EQUALITY DIVERSITY AND INCLUSION AIMS AND GUIDING PRINCIPLES

OUR AIMS

- ELRIG will strive for cultural change, both for itself and the ELRIG community
- Rather than a policy we have developed the ELRIG Community's Guiding Principles
- We will communicate the journey and the conclusions
- The process and implementation of outcomes will be transparent
- Data and the ELRIG community will guide action
- Mechanisms will be put in place to ensure that accessibility is maximised at all events
- Guiding principles will be embedded in governance and all Work Groups daily activities

OUR GUIDING PRINCIPLES

We will promote equality, by welcoming all to all our events and will be inclusive, by removing barriers to access, and that our events will represent the diversity of the ELRIG community.

OUR EQUALITY PRINCIPLE IS:

We will ensure that all are welcome by: profiling the demographics of attendees by segment, age, ethnicity, disability and gender, monitoring and ensuring that no one group is favoured nor excluded and act to ensure equal outcomes and opportunities for the entire ELRIG community.

OUR DIVERSITY PRINCIPLE IS:

We will strive for gender balance at our events, by ensuring that the diversity mix of our speakers represents the diversity of our delegates, and that the diversity mix of our delegates represents the diversity of the ELRIG community, as well as ensuring that scientific content reflects the diversity of the ELRIG community.

OUR INCLUSIVITY PRINCIPLE IS:

We will ensure that accessibility is maximised at all events, by removing barriers to those with disabilities, limits on finances, caring and parental responsibilities, religious needs, geographical location and other requirements. To ensure our principles remain relevant, we will solicit, monitor, and report to the ELRIG community and act upon relevant feedback during and after events to maintain accessible and safe spaces in which to collaborate.

WELCOME TO RESEARCH & INNOVATION 2023

We are excited to welcome you to ELRIG's annual Research & Innovation conference which is back in Cambridge!

This year we will learn how emerging biology and cutting-edge technologies are coming together to pioneer the medicines of the future. Over the two days, our four themed sessions will address different aspects of innovation across drug discovery and place an emphasis on bold ideas and our shared ambitions to treat, cure and benefit more patients globally. We are also honoured to be joined by our two plenary keynote speakers who will be complementing the excellent scientific content in our tracks; Ron Weiss (Professor of Biological Engineering, MIT) and Ken Raj (Principal Investigator, Altos Labs), will share leading edge academic and industrial research along with their perspectives on the developments within synthetic biology and the longevity research fields.

The planning and organisation of this meeting was due to the efforts of many individuals. In particular, we would like to thank our session chairs: Lynne Cox (University of Oxford), David Fischer (Charles River Laboratories), Kathryn Giblin (AstraZeneca), Joanne Hackett (IQVIA), Janet Lord (University of Birmingham), Gary Pairaudeau (Exscientia), Simon Todd (AstraZeneca) and Ron Weiss (MIT), together with the ELRIG Team.

We look forward to welcoming you to this event and hope that you enjoy a stimulating and rewarding two days.

CONFERENCE DIRECTORS



Saleha Patel

Associate Principal Scientist, Emerging Innovations, Discovery Sciences, AstraZeneca, R&D, Cambridge, UK



Roger Clark

Head of HTS, Charles River Labs

PLENARY KEYNOTE SPEAKERS



Ron Weiss
Professor, Massachusetts Institute of Technology

MAMMALIAN SYNTHETIC BIOLOGY AND PROGRAMMABLE ORGANOIDS

29th March 2023, 09:40
The Auditorium

Mammalian synthetic biology has recently emerged as a field that is revolutionizing how we design and engineer biological systems for diagnostic and medical applications. In this talk, we will describe our integrated computational / experimental approach to engineering complex behavior in mammalian cells with applications to Programmable Organoids derived from hiPS cells. In our research, we apply design principles from electrical engineering and other established fields. These principles include abstraction, standardization, modularity, and computer aided design. But, we also spend considerable effort towards understanding what makes synthetic biology different from all other existing engineering disciplines by discovering new design and construction rules that are effective for this unique discipline. We will present Programmable Organoids, a new platform for drug discovery that enables rapid

and effective drug screening. Based on programmed differentiation into synthetic mammalian tissues having multiple cell type architectures that are similar to human organs, Programmable Organoids mimic the response of a target organ to both positive and negative effects of drug candidates. Factors that can be non-destructively measured include cell state, viability, and function. Because they are synthetic, Programmable Organoids can host a large array of live-cell biosensors, built-in to one or more cell types, providing a rapid and realtime spatial readout of pathway-specific biomarkers including miRNAs, mRNAs, proteins, and other metabolites. Organoids programmed with both general and disease specific sensors then provide detailed information that can be used to identify candidates for further analysis. We envision a programmable common platform that can be shared among multiple drug candidates.



Ken Raj
Principal Investigator, Altos Labs Cambridge Institute of Science

NEW PERSPECTIVE ON AN AGE-OLD QUESTION

30th March 2023, 09:35
The Auditorium

Why we age, is arguably one of the oldest unanswered questions that spawned multiple hypotheses, all of which remain to be unequivocally proven. In recent years however, our understanding of ageing has been impacted by several seminal discoveries from different fields of biology. Although the details of these discoveries have yet to be fully elucidated, the nature of their effects is already sufficiently radical and clear, that it challenges the long-held intuitive perspectives of why and how we age. In particular, the last half century of gene-centric research,

which has brought immeasurable understanding of biology, is found wanting in this regard. Besides ushering in a new perspective that is a genuine step change from the old, it also challenges the fundamentals of drug discovery, which has hitherto been focused on gene target screening. These changes and challenges will be addressed together with a description of how a new and different model of knowledge acquisition is being brought to bear on the very old question of ageing and health.

INFORMATION FOR PARTICIPANTS

REGISTRATION

To help keep Research & Innovation 2023 a safe space, we require the following from all attendees:

1. Pre-registration for the meeting is essential. Please register at elrig.org and enter our EventFlo registration system (*if you wish to, you may choose a pro-noun, which will be printed on your badge*).
2. Please observe our safe space guidelines:
At ELRIG we want all our meeting participants, whether the meeting is face-to-face or on-line, to enjoy, participate in and contribute to the event. We are therefore dedicated to providing a harassment-free experience for all event participants involved in its activities and meetings. ELRIG does not accept harassment or intimidation of ELRIG participants in any form whether verbal, physical, or written (including on social media or by email).

Harassment includes, but is not limited to:

1. Offensive or unwanted conduct on the basis of age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex or sexual orientation which has the purpose or effect of violating dignity or creating an intimidating, hostile or degrading environment.
2. Use of sexualised or other inappropriate images or unwelcome sexualised content, inappropriate physical contact, unwelcome sexual attention or stalking.
3. Sustained interruption of speakers or those asking questions.
4. Unwanted photography or filming.

Intimidation includes, but is not limited to:

1. Making threats.
2. Bullying.
3. Personal attacks.

Participants who do not adhere to these rules will be asked to stop and expected to comply immediately. Participants may be removed from any meeting or communications at the discretion of ELRIG's management if this behaviour continues. If you are being harassed/ intimidated, notice that someone else is being harassed/ intimidated, or have any other concerns, please contact any of the ELRIG management team immediately. They will be able to step in to remove you or others from a chain of communication, if this is the preferred action, and can also facilitate a discussion or mediation. If you wish, you may also nominate someone else to support facilitating any mediation or as an observer to this process.

SITE INFORMATION

- Available toilets, including a disabled toilet, can be found inside the conference centre building.
- There is an available Family Room situated in the corridor behind conference reception. Anyone wishing to use this room for their purpose, can go to the main reception and ask for directions.

WIFI

Wi-Fi is freely available throughout the venue and may be found by following the below instructions:

1. Join the 'ConferenceGuest' network.
2. Enter your name and email address to register.
3. Click continue to send a registration confirmation email to that email address.
4. Open the registration email, follow the 'click here' link, and confirm the address is valid. (If you don't do this you will only get 10 minutes of free Wi-Fi).

ELRIG MOBILE APP

Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.



- View the event programme
- View presentation and poster abstracts
- View speaker profiles
- View the exhibitor guide
- View the delegate and exhibitor list
- Organise your day with your own favourites list
- Share your profile as vCard and QR Code and scan exhibitor QR code information tags
- Network – contact delegates, other exhibitors and speakers easily through opt-in directories and integration with Linked-In, Twitter and Facebook

You can download the ELRIG app by visiting the app store appropriate to your tablet or smart phone, scanning the QR code below or visiting the ELRIG website:

redesign.elrig.org/mobile_app



FLOOR PLAN



TRACK SUMMARY

SYNTHETIC BIOLOGY: GENETICALLY PROGRAMMED HEALTHCARE

29th March 2023
The Auditorium

SESSION CHAIRS

Ron Weiss
Massachusetts Institute of Technology
Simon Todd
AstraZeneca

Synthetic biology is enabling drug development by improving the ability of scientists to design and engineer biological systems for specific purposes. These approaches can potentially lead to faster, more efficient, and more

cost-effective, sustainable drug development. Furthermore, programmable gene circuits can provide novel functionality and control to therapeutic systems, thereby creating entirely new classes of cell and gene therapies.

08.30-09.30	Registration
09.30-09.35	ELRIG Welcome - Melanie Leveridge, GlaxoSmithKline & ELRIG Chair
09.35-09.40	Conference Director Welcome & Keynote Introduction - Saleha Patel, AstraZeneca & Roger Clark, Charles River Labs
09.40-10.25	Plenary Keynote - Mammalian synthetic biology and programmable organoids - Ron Weiss, Massachusetts Institute of Technology
10.25-11.00	Refreshment Break
11.00-11.10	Session Chair Introduction - Synthetic biology: genetically programmed healthcare - Ron Weiss, Massachusetts Institute of Technology & Simon Todd, AstraZeneca
11.10-11.40	Utilizing synthetic biology to advance therapeutics - Tara Deans, University of Utah
11.40-12.10	TBC - Caleb Bashor, William Marshall Rice University
12.10-13.00	CoSolve Sustainability - Novel solutions to enable organic solvent recycling from R&D processes - Kelly Gray, AstraZeneca
13.00-14.00	Refreshment Break with Poster Session 13.30-14.00
14.00-14.30	Steering cellular phenotypes using mathematical modelling and feedback control - Lucia Marucci, University of Bristol
14.30-14.35	Technology Spotlight Partner - High-Throughput Plasmid Purification on the CyBio FeliX Liquid Handler - Muji Shah, Promega
14.35-14.40	Technology Spotlight Partner - BMG LABTECH - microplate reader specialists, introduce keeping cool as a way to enhance assay stability! - Catherine Walk, BMG LABTECH
14.40-15.10	Learning to program patterning and morphogenesis with synthetic genetic circuits - Leonardo Morsut, University of Southern California
15.10-15.20	Poster Presentation
15.20-15.50	Refreshment Break
15.50-16.20	Development of compact gene control tools using high-throughput measurements - Lacra Bintu, Stanford University
16.20-16.35	Industry Insider Partner - Oxford Nanopore Technologies - a look into the complete genome - Rachel Hipkin, Oxford Nanopore Technologies
16.35-17.05	Epigenome Engineering, Synthetic Immunotherapy, and Better Cell Therapy - Lei Stanley Qi, Stanford University
17.05-19.00	Networking in The Exhibition Hall - with Poster Session 17.30-18.00

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

TRACK SUMMARY

ULTRA-RARE DISEASE DRUG DISCOVERY AND PERSONALIZED THERAPIES

29th March 2023
The Rosalind Franklin Room

SESSION CHAIRS

David Fischer
Charles River
Joanne Hackett
IQVIA

With improved (genetic) diagnosis and federated analytics for finding patients, we have come to realize that rare diseases are not so rare after all. Recent developments in drug development, including gene therapy and oligonucleotide therapy approvals are also opening

up avenues for personalized or n=1 drugs. Clinical development is furthermore adapting to use biomarkers, single patient experimental medicine and decentralised clinical trials.

09.30-11.00	Content in The Auditorium
11.00-11.10	Session Chair Introduction - Ultra-rare disease drug discovery and personalized therapies - Joanne Hackett, Charles River Labs & David Fischer, IQVIA
11.10-11.40	Novel therapies in developmental and epileptic encephalopathies - Amy McTague, UCL
11.40-12.10	Using patient data to enable drug discovery in rare diseases - Guido Hartmann, Centogene
12.10-13.00	CoSolve Sustainability - Novel solutions to enable organic solvent recycling from R&D processes - Kelly Gray, AstraZeneca - <i>in The Auditorium</i>
13.00-14.00	Refreshment Break with Poster Session 13.30-14.00
14.00-14.30	Realising the benefit to healthcare through population-wide application of polygenic risk scores - Gilean McVean, Genomics plc
14.30-14.35	Technology Spotlight Partner - Advanced Spectral Cell Sorting Solutions For Immune Monitoring And Cell Purification - Katrina Kidd, Cytekbio
14.35-14.40	Technology Spotlight Partner - 3-D patient-derived models of rare cancers - Rebecca Charlton, LGC, ATCC
14.40-15.10	Development of antisense oligonucleotide therapeutics for the treatment of TUBB4A-related leukodystrophies - Laure Humbert, SynaptixBio
15.10-15.20	Poster Presentation
15.20-15.50	Refreshment Break
15.50-16.20	AI Augmented Target Discovery - Anne Phelan, Benevolent AI
16.20-16.35	Industry Insider Partner - Cell and Gene Therapy: the ddPCR Solution - Jose Martins, Bio-Rad
16.35-17.05	Nonclinical Development for Rare/Ultra-rare diseases; a Balance of Safety Assessment and High Need - Michael Templin, Charles River Labs 
17.05-19.00	Networking in The Exhibition Hall - with Poster Session 17.30-18.00

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

TRACK SUMMARY

AGE-OLD CHALLENGES, MODERN SOLUTIONS: THE ROLE OF GEROSCIENCE IN ADDRESSING AGE-RELATED DISEASES

30th March 2023
The Auditorium

SESSION CHAIRS

Janet Lord
University of Birmingham
Lynne Cox
University of Oxford

Lifespan is increasing but healthy life expectancy is not keeping pace – we are living longer but not healthier. Geroscience aims to treat age-related diseases by

addressing core ageing processes; novel drug discovery approaches have the potential to help deliver this objective.

09.00-09.30	Registration
09.30-09.35	Conference Director Welcome & Keynote Introduction - Saleha Patel, AstraZeneca & Roger Clark, Charles River Labs
09.35-10.20	Plenary Keynote - New perspective on an age-old question - Ken Raj, Altos Labs Cambridge Institute of Science
10.20-10.25	Early Career Professional Impact Award Introduction - Del Trezise, Sartorius AG
10.25-10.40	ELRIG - Early Career Professional Impact Award - Remote and Selective Control of Astrocytes by Magnetomechanical Stimulation - Yichao Yu, University College London
10.40-11.15	Refreshment Break
11.15-11.20	Session Chair Introduction - Age-Old Challenges, Modern Solutions: The Role of Geroscience in Addressing Age-Related Diseases - Janet Lord, University of Birmingham & Lynne Cox, University of Oxford
11.20-11.50	Longevity Pharmacology Comes of Age - Joao Pedro de Magalhaes, University of Birmingham
11.50-11.55	Technology Spotlight Partner
11.55-12.10	Industry Insider Partner - From Target Engagement to Cellular Effect. How to Position CETSA in the Drug Discovery Process - Yasmin Andersson, Pelago Bioscience AB
12.10-12.40	UK SPINE, targeting drug discovery for age-related multimorbidity - Graeme Wilkinson, Medicines Discovery Catapult
12.40-13.20	CoSolve Sustainability - Novel technologies to enable filter tip reuse or recycling in research and development - Kelly Gray, AstraZeneca
13.20-14.20	Refreshment Break with Poster Session 13.30-14.00
14.20-14.50	Oligonucleotide senotherapeutics for the diseases of ageing - Lorna Harries, Institute of Biomedical and Clinical Science 
14.50-15.20	Providing in vivo data on ageing endpoint early in drug discovery - David Weinkove, Magnitude Biosciences
15.20-15.30	Poster Presentation
15.30-15.40	Comfort Break
15.40-16.10	Strategies to target senescence - Jesus Gil, MRC London Institute of Medical Sciences
16.10-16.40	Autophagy as a pathway to rejuvenate immune responses - Ghada Alsaleh, University of Oxford

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

TRACK SUMMARY

THE RISE OF AI DRIVEN DRUG DISCOVERY

30th March 2023
The Rosalind Franklin Room

SESSION CHAIRS

Garry Pairaudeau
Exscientia
Kathryn Giblin
AstraZeneca

We are seeing a revolution in the application of AI to improve decision making in drug discovery. This session will focus on presenting and evaluating emerging

technologies and innovations in AI which promise to drive drug discovery research in the future.

09.30-11.15	Content in The Auditorium
11.15-11.20	Session Chair Introduction - The rise of AI driven drug discovery - Garry Pairaudeau, Exscientia & Kathryn Giblin, AstraZeneca
11.20-11.50	Accelerating Drug Discovery with Computer Vision - Greg Slabaugh, Queen Mary University of London
11.50-11.55	Technology Spotlight Partner - Streamlining Drug Discovery with VectorBuilder - Dan Rosenthal, VectorBuilder
11.55-12.10	Industry Insider Partner - ML Tools in Drug Discovery - Thomas Waldmann, WuXi AppTec
12.10-12.40	Predictive Minisci and P450 Late Stage Functionalization with Transfer Learning - Emma King-Smith, University of Cambridge
12.40-13.20	CoSolve Sustainability - Novel technologies to enable filter tip reuse or recycling in research and development - Kelly Gray, AstraZeneca - <i>in The Auditorium</i>
13.20-14.20	Refreshment Break with Poster Session 13.30-14.00
14.20-14.50	Learning rich molecular representations from quantum mechanics - Ward Haddadin, Exscientia
14.50-15.20	Federated Learning in Drug Discovery - Lewis Mervin, Astrazeneca
15.20-15.30	Poster Presentation
15.30-15.40	Comfort Break
15.40-16.10	Mapping the Rare Disease Knowledge Graph - Daniel O'Donovan, healx
16.10-16.40	Human-in-the-loop modelling for de novo molecular generation - Samuel Kaski, University of Manchester and Aalto University

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

DEVELOPING LIFE-CHANGING MEDICINES IN A WAY THAT IS RESPECTFUL OF OUR PLANET

Our future depends on healthy people, a healthy society, and a healthy planet. At AstraZeneca, we're using our knowledge of science and ability to innovate to help deliver sustainable healthcare. Our CoSolve programme allows us to connect with, and crowdsource, novel solutions to address our toughest sustainability challenges.

We are committed to delivering solutions and impact across our three interconnected sustainability priorities; Access to healthcare, Environmental protection, and Ethics and transparency.

Sustainability is embedded into everything we do. Through our Ambition Zero Carbon programme, we are taking bold action on climate change, and we are proud of our efforts to reduce the environmental impact of our research labs, recognised by our 'Gold level' certification through the collaboration with 'My Green Lab'. As part of our commitment, we are continuously striving to identify and adopt sustainability solutions that transform our ways of working in the laboratory and deliver on our goals.

We have been looking for innovators from all disciplines with novel solutions to our sustainability challenges that we launched in October 2022. Join us for the live pitching event on both days where you will hear ideas from our three finalists for each track and vote for your favourite!

OUR CHALLENGES

Challenge #1: Novel technologies to enable filter tip reuse or recycling in research and development

Unlike standard pipette tips, filter tips, cannot be washed, sterilised and reused multiple times due to limitations associated with the filters being washed or autoclaved. We want to introduce a novel solution that reduces the volume of single use filter tips entering the waste system for incineration, that does not compromise the reliability of experiments through contamination.

We have been looking for ideas or methods that can either remove the filters from the tips to enable their reuse and/or recycling or provide an alternative to standard filter tips.

Challenge #2: Novel solutions to enable organic solvent recycling from R&D processes

Implementing organic solvent recovery suitable for reuse is an opportunity to address a key sustainability challenge. We have been seeking novel methodologies for organic solvent recovery that generates a product that does not present a risk to future processes if reused. Key areas of interest include (but are not limited to) recovering:

- solvents such as acetonitrile from HPLC
- solvent including DMSO used in chemical processes

MEET OUR FINALISTS



Vesna Najdanovic
Senior Lecturer and Deputy Head of the Chemistry and Chemical Engineering Department, College of Engineering and Physical Sciences, Aston University



Katrina Cornish
Endowed Chair and Ohio Research Scholar, Bioemergent Materials & Research Director, Program of Excellence in Natural Rubber Alternatives



Nenko Nenov
Owner and Developer, InnoSolv LLC



Mohammed Ali
Professor, Department of Mechanical Engineering, King Saud University, Saudi Arabia



Sara Salvador Cob
Scientific Researcher, VITO



Alberto Portone
Researcher, TPM, Science & Technology Park for Medicine

JOIN THE LIVE PITCHING EVENT!



One winner for each challenge will be selected by our expert panel of judges. Winners have the opportunity to be awarded up to \$25K to fund the progression of their idea into a real-life, tangible solution. Winners will be announced

on our social media channel following the event and you can also hear an extended presentation on the winning solutions at the ELRIG Sustainability Practices in Drug Discovery Research Forum in Oxford on 19 April 2023.

LIVE PITCHING SESSION DAY 1

Timings	Novel solutions to enable organic solvent recycling from R&D processes
12.10	Session Chair Introduction - Kelly Gray, Open Innovation Programme Manager, AstraZeneca
12.15	Opening Address - Maurits van Tol, CTO Johnson Matthey
12.30	Pitch 1 - Green solvents and solutions for solvent recycling - Vesna Najdanovic
12.40	Pitch 2 - A novel nitrogen assisted method for acetonitrile recovery from HPLC - Nenko Nenov
12.50	Pitch 3 - Purification and recovery of organic solvents with membrane technology - Sara Salvador Cob

MEET OUR JUDGES



Maurits van Tol
CTO,
Johnson Matthey



Anthony Michetti
Director of Sustainability,
Cell Signaling Technology



Saleha Patel
Associate Principal Scientist,
Emerging Innovations, Discovery
Sciences, AstraZeneca, R&D,
Cambridge, UK

LIVE PITCHING SESSION DAY 2

Timings	Novel technologies to enable filter tip reuse or recycling in research and development
12.40	Introduction & Opening Address - Kelly Gray, Open Innovation Programme Manager, AstraZeneca
12.55	Pitch 1 - Sustainable technologies to enable filter tip reuse and recycling in research and development - Katrina Cornish
13.05	Pitch 2 - Using filters as new thermal insulation materials - Mohamed Ali
13.15	Pitch 3 - Filter-remover box to recycle or reuse tips - Alberto Portone



Verena Brucklacher-Waldert
Head of Immune Cell-based Services,
Horizon Discovery/PerkinElmer &
ELRIG Board Director



Christian Herget
Head of BU Bioscience,
Greiner Bio-One



VOTE FOR YOUR FAVOURITE IDEA!

A slido poll will be open during each session. Simply scan the QR code and vote for your favourite idea.

RESEARCH & INNOVATION 2023 SPONSORS

INDUSTRY INSIDER SPONSORS



Bio-Rad
bio-rad.com



Oxford Nanopore
Technologies
nanoporetech.com



Pelago Bioscience
pelagobio.com



WuXi AppTec
wuxiapptec.com

TECHNOLOGY SPOTLIGHT PARTNER



LGC – ATCC
atcc.org



BMG LABTECH
bmglabtech.com



Cytek Biosciences
cytekbio.com



Promega
promega.co.uk

STANDARD SPONSORS



AMSBIO
amsbio.com



Analytik Jena UK
analytik-jena.com/uk



Beckman Coulter
beckman.com



BioAscent Discovery
bioascent.com



BlueCatBio
bluecatbio.com



Cambridge BioScience
bioscience.co.uk



Cellbox Solutions
cellbox-solutions.com



Cellular Highways
cellularhighways.com



Collaborative Drug
Discovery
collaborativedrug.com



Flow Robotics
flow-robotics.com



Formulatrix
formulatrix.com



Greiner Bio-One
gbo.com



Hamilton
hamiltoncompany.com



HexagonFab
hexagonfab.com



Integra Biosciences
integra-biosciences.com



Lablogic Systems
lablogic.com



Miltenyi Biotec
miltenyibiotec.com



New England Biolabs
neb.uk.com



Selvita
selvita.com



UPM-Kymmene
Corporation
upmbiomedicals.com



VectorBuilder
en.vectorbuilder.com

ELRIG EVENTS 2023

KEY EVENTS

ELRIG is a learned society that organises scientific conferences and forums, for the European drug discovery community. Meetings will have anywhere between 40 to 1500 attendees. Meetings may be an afternoon only to 2 days in length and have a very narrow focus or contain a broad range of topics, applicable to many research areas within the drug discovery community. All events are free-to-attend, simply register at elrig.org.



2023 CONFERENCES

ELRIG THERAPEUTIC OLIGO AND EUROPEAN CHEMICAL BIOLOGY SYMPOSIUM 2023

AstraZeneca, Gothenburg
May 9th - 11th

DRUG DISCOVERY 2023

ACC Liverpool
October 18th - 19th

HIGH CONTENT IMAGING AND FLOW CYTOMETRY IN DRUG DISCOVERY 2023

GSK, Stevenage
November 21st - 22nd

2023 NETWORKING EVENTS

CAMBRIDGE

May 23rd

LONDON

June 29th

2023 FORUMS

LABEL-FREE MASS SPECTROMETRY ASSAYS FOR EARLY DRUG DISCOVERY

The Netherlands
January 25th

SUSTAINABILITY PRACTICES IN DRUG DISCOVERY RESEARCH

Oxford
April 19th

THE SCOTTISH RESEARCH AND DRUG DEVELOPMENT FORUM

Scotland
April 27th

DISCOVERY TECHNOLOGIES 2023: COMPLEX MEDICINES FORUM

Liverpool
June 20th

ADVANCEMENTS IN CELL & GENE THERAPY: NEW THERAPEUTIC HORIZONS

Basel
September 15th

FRENCH DRUG DISCOVERY FORUM

France
December 6th

All events are in-person and free of charge to attend, but registration is essential.

